Current and emerging treatment options for fecal incontinence

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social and economic burdens. The aim of this article is to provide an overview of current and emerging treatment options for FI. A MEDLINE search was conducted for Englishlanguage articles related to FI prevalence, etiology, diagnosis, and treatment published from January 1, 1990 through June 1, 2013. The search was extended to unpublished trials on Clinical- Trials.gov and relevant publications cited in included articles. Conservative approaches, including dietary modifications, medications, muscle-strengthening exercises, and biofeedback, have been shown to provide short-term benefits. Transcutaneous electrical stimulation was considered ineffective in a randomized clinical trial. Unlike initial studies, sacral nerve stimulation has shown reasonable short-term effectiveness and some complications. Dynamic graciloplasty and artificial sphincter and bowel devices lack randomized controlled trials and have shown inconsistent results and high rates of explantation. Of injectable bulking agents, dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx) has shown significant improvement in incontinence scores and frequency of incontinence episodes, with generally mild adverse effects. For the treatment of FI, conservative measures and biofeedback therapy are modestly effective. When conservative therapies are ineffective, invasive procedures, including sacral nerve stimulation, may be considered, but they are associated with complications and lack randomized, controlled trials. Bulking agents may be an appropriate alternative therapy to consider before more aggressive therapies in patients who fail conservative therapies.

Original languageEnglish (US)
Pages (from-to)752-764
Number of pages13
JournalJournal of Clinical Gastroenterology
Volume48
Issue number9
DOIs
StatePublished - Oct 1 2014

Fingerprint

Fecal Incontinence
Randomized Controlled Trials
Diet Therapy
Therapeutics
Transcutaneous Electric Nerve Stimulation
Hyaluronic Acid
Complementary Therapies
Microspheres
MEDLINE
Publications
Economics
Clinical Trials
Exercise
Equipment and Supplies
Muscles
Injections

Keywords

  • Anal incontinence
  • Diarrhea
  • Motility
  • NASHA Dx
  • SNS

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current and emerging treatment options for fecal incontinence. / Rao, Satish Sanku Chander.

In: Journal of Clinical Gastroenterology, Vol. 48, No. 9, 01.10.2014, p. 752-764.

Research output: Contribution to journalReview article

@article{b4d0ff081a974c1cab6cfdf56dbc2bbc,
title = "Current and emerging treatment options for fecal incontinence",
abstract = "Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social and economic burdens. The aim of this article is to provide an overview of current and emerging treatment options for FI. A MEDLINE search was conducted for Englishlanguage articles related to FI prevalence, etiology, diagnosis, and treatment published from January 1, 1990 through June 1, 2013. The search was extended to unpublished trials on Clinical- Trials.gov and relevant publications cited in included articles. Conservative approaches, including dietary modifications, medications, muscle-strengthening exercises, and biofeedback, have been shown to provide short-term benefits. Transcutaneous electrical stimulation was considered ineffective in a randomized clinical trial. Unlike initial studies, sacral nerve stimulation has shown reasonable short-term effectiveness and some complications. Dynamic graciloplasty and artificial sphincter and bowel devices lack randomized controlled trials and have shown inconsistent results and high rates of explantation. Of injectable bulking agents, dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx) has shown significant improvement in incontinence scores and frequency of incontinence episodes, with generally mild adverse effects. For the treatment of FI, conservative measures and biofeedback therapy are modestly effective. When conservative therapies are ineffective, invasive procedures, including sacral nerve stimulation, may be considered, but they are associated with complications and lack randomized, controlled trials. Bulking agents may be an appropriate alternative therapy to consider before more aggressive therapies in patients who fail conservative therapies.",
keywords = "Anal incontinence, Diarrhea, Motility, NASHA Dx, SNS",
author = "Rao, {Satish Sanku Chander}",
year = "2014",
month = "10",
day = "1",
doi = "10.1097/MCG.0000000000000180",
language = "English (US)",
volume = "48",
pages = "752--764",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Current and emerging treatment options for fecal incontinence

AU - Rao, Satish Sanku Chander

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social and economic burdens. The aim of this article is to provide an overview of current and emerging treatment options for FI. A MEDLINE search was conducted for Englishlanguage articles related to FI prevalence, etiology, diagnosis, and treatment published from January 1, 1990 through June 1, 2013. The search was extended to unpublished trials on Clinical- Trials.gov and relevant publications cited in included articles. Conservative approaches, including dietary modifications, medications, muscle-strengthening exercises, and biofeedback, have been shown to provide short-term benefits. Transcutaneous electrical stimulation was considered ineffective in a randomized clinical trial. Unlike initial studies, sacral nerve stimulation has shown reasonable short-term effectiveness and some complications. Dynamic graciloplasty and artificial sphincter and bowel devices lack randomized controlled trials and have shown inconsistent results and high rates of explantation. Of injectable bulking agents, dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx) has shown significant improvement in incontinence scores and frequency of incontinence episodes, with generally mild adverse effects. For the treatment of FI, conservative measures and biofeedback therapy are modestly effective. When conservative therapies are ineffective, invasive procedures, including sacral nerve stimulation, may be considered, but they are associated with complications and lack randomized, controlled trials. Bulking agents may be an appropriate alternative therapy to consider before more aggressive therapies in patients who fail conservative therapies.

AB - Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social and economic burdens. The aim of this article is to provide an overview of current and emerging treatment options for FI. A MEDLINE search was conducted for Englishlanguage articles related to FI prevalence, etiology, diagnosis, and treatment published from January 1, 1990 through June 1, 2013. The search was extended to unpublished trials on Clinical- Trials.gov and relevant publications cited in included articles. Conservative approaches, including dietary modifications, medications, muscle-strengthening exercises, and biofeedback, have been shown to provide short-term benefits. Transcutaneous electrical stimulation was considered ineffective in a randomized clinical trial. Unlike initial studies, sacral nerve stimulation has shown reasonable short-term effectiveness and some complications. Dynamic graciloplasty and artificial sphincter and bowel devices lack randomized controlled trials and have shown inconsistent results and high rates of explantation. Of injectable bulking agents, dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx) has shown significant improvement in incontinence scores and frequency of incontinence episodes, with generally mild adverse effects. For the treatment of FI, conservative measures and biofeedback therapy are modestly effective. When conservative therapies are ineffective, invasive procedures, including sacral nerve stimulation, may be considered, but they are associated with complications and lack randomized, controlled trials. Bulking agents may be an appropriate alternative therapy to consider before more aggressive therapies in patients who fail conservative therapies.

KW - Anal incontinence

KW - Diarrhea

KW - Motility

KW - NASHA Dx

KW - SNS

UR - http://www.scopus.com/inward/record.url?scp=85027927875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027927875&partnerID=8YFLogxK

U2 - 10.1097/MCG.0000000000000180

DO - 10.1097/MCG.0000000000000180

M3 - Review article

C2 - 25014235

AN - SCOPUS:85027927875

VL - 48

SP - 752

EP - 764

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 9

ER -